Original Source(s)
Related Content
FDA Approves Gedatolisib in Breast Cancer
In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.
July 14, 2026
-
2 min
Dana-Farber Research News 06.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 - 31.
Comprehensive Cancer Care for the Doral Community
Baptist Health Cancer Care is now serving patients in Doral with a comprehensive, community-based approach to oncology care designed to make treatment more convenient and accessible for both patients and referring physicians.
